Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Blauvelt

Dermatology Portland, OR Medical Doctor

NPI 1932115425 CMS profile 314007

9495 Sw Locust Street, Suite A, Portland, OR 97223

Open in the dashboard

General payments

$1,800,372

1,152 records reported · program years 2019–2025

Research payments

$252,851

Paid to them · 295 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$16,999,238 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Andrew Blauvelt of Portland, OR is reported in the CMS Open Payments database as having received $1,800,372 across 1,152 general payments and $252,851 in research payments paid to them. Separately, studies naming them as principal investigator received $16,999,238 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $250,246 186
2025 Research $3,000 3
2024 General $263,916 196
2024 Research $4,640 4
2023 General $313,199 207
2023 Research $12,706 17
2022 General $324,768 199
2022 Research $34,261 27
2021 General $182,403 53
2021 Research $51,323 88
2020 General $193,582 91
2020 Research $92,691 100
2019 General $272,256 220
2019 Research $54,230 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Blauvelt
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Andrew Blauvelt were reported at $250,246. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Andrew Blauvelt Dermatology median Middle half National median
2019 $272,256 $454 $129–$1,240 $163
2020 $193,582 $235 $81–$756 $114
2021 $182,403 $377 $108–$1,108 $132
2022 $324,768 $514 $143–$1,391 $149
2023 $313,199 $607 $159–$1,674 $160
2024 $263,916 $751 $204–$1,903 $164
2025 $250,246 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $357,964 231 payments
  2. Lilly USA, LLC $326,714 221 payments
  3. UCB, Inc. $235,272 177 payments
  4. E.R. Squibb & Sons, L.L.C. $160,531 82 payments
  5. Eli Lilly and Company $147,489 78 payments
  6. Pfizer Inc. $91,399 29 payments
  7. Genzyme Corporation $76,781 45 payments
  8. Regeneron Healthcare Solutions, Inc. $65,118 60 payments
  9. LEO Pharma Inc. $52,456 25 payments
  10. LEO Pharma AS $36,911 19 payments
  11. Other $249,736 185 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $905,474 259 payments
  2. Consulting Fee $731,172 268 payments
  3. Travel and Lodging $109,556 353 payments
  4. Honoraria $31,750 7 payments
  5. Food and Beverage $14,199 261 payments
  6. Education $8,221 4 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $177,609 100 payments
  2. Bimzelx $166,520 116 payments
  3. EBGLYSS $129,668 88 payments
  4. SKYRIZI $107,505 70 payments
  5. OLUMIANT $98,724 60 payments
  6. SOTYKTU $72,720 47 payments
  7. DUPIXENT Inflammation And Immunology $65,118 60 payments
  8. DUPIXENT Immunology $62,124 21 payments
  9. TREMFYA $44,617 32 payments
  10. CIBINQO $33,770 9 payments
  11. Other $140,997 119 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $85,868 139 payments
  2. UCB, Inc. $83,760 84 payments
  3. Pfizer Inc. $35,100 31 payments
  4. Eli Lilly and Company $23,375 7 payments
  5. Novartis Pharmaceuticals Corporation $15,042 20 payments
  6. Genzyme Corporation $5,500 10 payments
  7. AbbVie, Inc. $3,007 3 payments
  8. LEO Pharma AS $1,200 1 payment

Records

1,447 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record